Full-Time

Junior Science Analyst

Posted on 9/13/2024

Tempus

Tempus

1,001-5,000 employees

AI-driven healthcare data analysis platform

AI & Machine Learning
Biotechnology
Healthcare

Compensation Overview

$60k - $75kAnnually

+ Incentive Compensation + Restricted Stock Units

Entry

Chicago, IL, USA

Hybrid position requiring in-office presence.

Category
Bioinformatics
Genomics
Biology Lab & Research
Biology & Biotech
Requirements
  • Must have a BS or MS degree in Cancer Genetics, Human Genetics, Biological Sciences or related scientific field with a strong background in molecular biology.
  • Must have utmost attention to detail, excellent communication, and writing skills.
  • Must be able to accurately follow formal documentation and protocols.
  • Ability to work in both an individual and group setting. Must be flexible and able to adjust priorities according to workload or management needs.
Responsibilities
  • Utilize internal and external software and tools to analyze RNA data for clinically reportable fusions
  • Read and interpret scientific literature and curate relevant findings in a clear, concise, and precise manner
  • Review clinical documentation to help determine appropriate diagnoses
  • Communicate with Tempus team members, including Clinical Science, Pathology, Bioinformatics, Report Generation Project Managers, as appropriate, to analyze and complete clinical cases.

Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in healthcare. The company offers a platform that analyzes medical data to provide insights for physicians, helping them make better treatment decisions. This platform also aids pharmaceutical and biotech companies in drug development by identifying new targets and assessing treatment effectiveness. For patients, Tempus identifies personalized therapy options, particularly in cancer care, where their research has shown increased opportunities for tailored treatments. They have developed a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Tempus generates revenue by charging healthcare providers and companies for access to their platform and insights, setting them apart from competitors by their focus on personalized medicine and extensive cancer research.

Company Stage

IPO

Total Funding

$894.9M

Headquarters

Chicago, Illinois

Founded

2015

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • Increased AI adoption in healthcare boosts Tempus' partnerships and collaborations.
  • Acquisition of Ambry Genetics expands Tempus' genetic testing capabilities.
  • Integration with Flatiron's OncoEMR enhances precision in cancer treatment plans.

What critics are saying

  • Competition from partners like Genialis may lead to conflicts of interest.
  • Ambry Genetics acquisition could pose financial risks if synergies aren't realized.
  • Technical challenges may arise in integration with Flatiron's OncoEMR platform.

What makes Tempus unique

  • Tempus uses AI to analyze clinical and molecular data for precision medicine.
  • Their platform aids in personalized treatment decisions for cancer patients.
  • Tempus collaborates with biotech firms to enhance drug development using real-world data.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Relocation Assistance

Company Equity

Performance Bonus

INACTIVE